undamentalytics Newsletter
Sign in

Champions Oncology, Inc. income statement

In fiscal 2026, Champions Oncology, Inc. reported revenue of $59.4m, up 4.4% on the year before, operating income of −$1.1m (a -1.9% margin) and net income of −$1.2m, or −$0.08 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Apr 20182019Apr 20192020Apr 20202021Apr 20212022Apr 20222023Apr 20232024Apr 20242025Apr 20252026Apr 2026LTMJul 2026
Revenue20273241495450575961
Cost of revenue——1721243029283130
Gross profit——1520252421292930
Research and development456791210799
Selling and marketing33466778911
General and administrative45779101191111
Operating income−10−201−5−75−1−1
Income before tax−10−201−5−75−1−1
Income tax000000−0−000
Net income−10−201−5−75−1−1
Diluted EPS−$0.13$0.01−$0.18$0.02$0.04−$0.39−$0.54$0.33−$0.08−$0.08
Diluted shares (average)11m14m12m15m14m14m14m14m14m14m
EBITDA−11−112−3−5600

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CSBR vs PRPOCSBR vs MASSCSBR vs PSNL

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Champions Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Champions Oncology, Inc.